Arecor와 TRx Biosciences 연구 협력
Arecor Therapeutics plc
("아레코" 또는 "회사")
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
- Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability
- Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabetes and obesity
- Potential to expand collaboration across multiple oral peptide products and combination therapies in growing global market
Cambridge, UK, 12 March 2024: Arecor Therapeutics plc(AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, and TRx Biosciences Limited, a drug development company applying novel lipid technology to the oral delivery of challenging molecules, today announced a research collaboration for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.
GLP-1 receptor agonists are a class of therapeutic peptides used to treat type 2 diabetes and obesity, in a global market predicted to reach $80-$100+ billion by 20301. Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability. Injection remains the most common delivery form for therapeutic peptide drugs, limiting adoption, compliance and usage among patients, who would prefer a simpler, more practical oral therapy.
The only GLP-1 receptor agonist currently available to patients in pill form - Novo Nordisk's semaglutide (Rybelsus®) - has oral bioavailability of less than 1%2. Using TRx Biosciences' LipiCore? oral delivery technology alongside Arecor's formulation platform, Arestat?, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.
Arecor의 CEO인 Sarah Howell은 다음과 같이 말했습니다. "As the global market for GLP-1 receptor agonists grows and their use increases, significant challenges remain in their oral delivery. With current treatment options mostly limited to injectable therapies, many patients in need are unable to benefit from these highly effective treatments. Arecor has an excellent track record developing difficult-to-achieve product profiles by deploying our Arestat? technology to develop unique formulations specifically designed to overcome patient-focussed challenges. Alongside TRx Biosciences and its expertise in targeted oral drug delivery, we have an opportunity to develop an enhanced oral GLP-1 receptor agonist product. In addition, if the initial research collaboration is successful, we would hope to leverage the technology to deliver other high value peptides via patient- preferred oral delivery formats. I look forward to providing further updates in due course."
Dr Robin Bannister, Chief Executive Officer of TRx Biosciences, said: "The effective oral delivery of peptides remains a 'holy grail', meaning patients that require the convenience of oral treatment can't access the benefits of new peptide therapies. By combining TRx's LipiCore? technology with Arecor's proven peptide expertise and Arestat? platform, we create the opportunity to access novel oral uptake channels and protect peptides from damage in the gastrointestinal tract to solve this fundamental challenge. Semaglutide, given its immense potential in the treatment of diabetes and obesity, is a highly attractive starting point. Success with semaglutide may offer a path to multiple oral peptide products with enhanced absorption and efficacy."
The collaboration provides scope for expansion, following the initial oral GLP-1 receptor agonist programme, to develop further oral peptide products. These include additional peptides and combination approaches which may be key in the treatment of obesity-related health conditions, as well as peptide products targeting multiple therapeutic areas.
-ENDS-
참고자료
1. Anti-Obesity Drug Sales Could Hit $80 Billion by 2030 블룸버그 인텔리전스
The increase in appetite for obesity drugs J.P. Morgan Global Research
Novo Nordisk faces several 'overlooked' trends including competition for Wegovy, warns investment bank 사전
2. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021 Oct;60(10):1335-1348. doi: 10.1007/s40262-021-01025-x. Epub 2021 May 10
자세한 내용은 문의하시기 바랍니다 :
Arecor Therapeutics plc | www.arecor.com |
CEO 사라 하웰 박사 | 전화 : + 44 (0) 1223 426060 이메일 : [이메일 보호] |
Susan Lowther, 최고 재무 책임자 | 전화 : + 44 (0) 1223 426060 이메일 : [이메일 보호] |
| |
Panmure Gordon (영국) 제한 (노마드와 Broker) | |
프레디 크로슬리, 엠마 얼(기업 금융) Rupert Dearden(기업 중개) | 전화 : + 44 (0) 20 7886 2500
|
WG 파트너스 LLP (금융 설계사) | |
나이젤 반스, 사티시 나다라자 데이비드 윌슨, 클라에스 스팽 | 전화 : + 44 (0) 203 705 9321 |
ICR 콘실리움 | |
크리스 가드너, 데이비드 데일리, 린지 네빌 | 전화 : + 44 (0) 20 3709 5700 이메일 : [이메일 보호] |
|
편집자 주
아레코 소개
Arecor Therapeutics plc는 기존 치료 제품의 향상을 통해 혁신적인 의약품을 시장에 출시함으로써 환자 치료를 변화시키는 글로벌 중심의 바이오제약 회사입니다. 혁신적인 독점 기술 플랫폼인 Arestat™을 적용하여 당뇨병 및 기타 적응증에 대한 독점 제품의 내부 포트폴리오를 개발하고 있으며 선도적인 제약 및 생명공학 회사와 협력하여 치료 제품을 제공하고 있습니다. 아레스타트? 플랫폼은 광범위한 특허 포트폴리오의 지원을 받습니다.
자세한 내용은 당사 웹 사이트를 참조하십시오. www.arecor.com
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.